REPL - NASDAQ
Replimune Group, Inc.
$10.54
+19%Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
At a Glance
Live SnapshotNo Revenue Data
REPL has not reported any revenue values in the available annual periods.
Replimune Group, Inc. Profit Bridge
Profitability Analysis
Replimune Group, Inc. Income Statement
REPL • NASDAQ
| Replimune Group, Inc. Income Statement | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
GROSS PROFIT | |||||||||
(0.0) | (0.0) | (0.0) | (4.6M) | (4.1M) | (1.8M) | (148K) | (109K) | (122K) | |
0.0 | 0.0 | 0.0 | -4.6M | -4.1M | -1.8M | -148K | -109K | -122K | |
OPERATING INCOME | |||||||||
(261.6M) | (234.8M) | (177.1M) | (116.9M) | (78.6M) | (53.1M) | (28.4M) | (17M) | (8.2M) | |
(0.0) | (0.0) | (0.0) | (36.3M) | (21.1M) | (17.4M) | (8.8M) | (5.7M) | (2.7M) | |
(189.4M) | (175M) | (126.5M) | (80.6M) | (57.5M) | (38.8M) | (22.2M) | (13.5M) | (6.9M) | |
-261.6M | -234.8M | -177.1M | -121.5M | -82.8M | -56.2M | -30.9M | -19.2M | -9.6M | |
PRE-TAX INCOME | |||||||||
(7.9M) | (6.7M) | (4.2M) | (2.2M) | (3.1M) | (1.9M) | (0.0) | (0.0) | (0.0) | |
13.2M | 16.7M | 5.8M | -1.8M | -2.1M | 505K | 0.0 | 0.0 | 0.0 | |
(72.2M) | (59.8M) | (50.6M) | (0.0) | (0.0) | -3.1M | (451K) | -2.1M | (626K) | |
14.8M | 19.4M | 3.1M | 278K | -915K | 3.6M | 112K | -473K | 1.9M | |
-246.8M | -215.4M | -174M | -121.2M | -83.7M | -52.6M | -30.8M | -19.7M | -7.7M | |
NET INCOME | |||||||||
(468K) | (408K) | (288K) | -3.2M | -2.8M | (0.0) | (0.0) | (0.0) | (0.0) | |
-247.3M | -215.8M | -174.3M | -118M | -80.9M | -52.6M | -30.8M | -19.7M | -7.7M |
SEC Filings
REPL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 10, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | November 06, 2025 | November 06, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 20, 2025 | October 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 18, 2025 | September 16, 2025 | 2025 |
Related Guides
Continue your REPL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.